3 research outputs found
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain metastasis; however, its efficacy in
preventing disease progression and the associated toxicity have questioned the clinical impact of this approach and emphasized
the need for alternative treatments. Given the limited therapeutic options available for these patients and the poor understand-
ing of the molecular mechanisms underlying the resistance of metastatic lesions to WBRT, we sought to uncover actionable
targets and biomarkers that could help to refine patient selection. Through an unbiased analysis of experimental in vivo models
of brain metastasis resistant to WBRT, we identified activation of the S100A9âRAGEâNF-ÎșBâJunB pathway in brain metastases
as a potential mediator of resistance in this organ. Targeting this pathway genetically or pharmacologically was sufficient to
revert the WBRT resistance and increase therapeutic benefits in vivo at lower doses of radiation. In patients with primary mela-
noma, lung or breast adenocarcinoma developing brain metastasis, endogenous S100A9 levels in brain lesions correlated with
clinical response to WBRT and underscored the potential of S100A9 levels in the blood as a noninvasive biomarker. Collectively,
we provide a molecular framework to personalize WBRT and improve its efficacy through combination with a radiosensitizer
that balances therapeutic benefit and toxicity
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow
Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 à 108/kg with a median of 2.7 à 108/kg. The PB cell dose ranged from 0.02 to 77 à 10 8/kg with a median of 9.3 à 108/kg. The median dose for patients receiving BM (2.7 à 108/kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow
PubMed ID: 12829583Several studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 à 10 8 /kg with a median of 2.7 à 10 8 /kg. The PB cell dose ranged from 0.02 to 77 à 10 8 /kg with a median of 9.3 à 10 8 /kg. The median dose for patients receiving BM (2.7 à 10 8 /kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology